Entrada Therapeutics, Inc. (TRDA): Capital Expenditures
$1.04M
Year ended 2025-12-31
-28.8%
3-year compound annual growth
-14.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.04M | -67.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $3.16M | -43.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $5.61M | +94.5% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $2.89M | -37.0% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $4.58M | +97.6% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $2.32M | n/a | 2022-03-15, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $1.04M | -67.0% |
| Celularity Inc (CELU) | 2024-12-31 | $161.0K | -84.6% |
| Alumis Inc. (ALMS) | 2025-12-31 | $653.0K | -62.3% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $177.0K | +168.2% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $50.0K | -94.5% |
| Verastem, Inc. (VSTM) | 2024-12-31 | $28.0K | n/a |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $16.0K | -92.8% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $5.0K | -64.3% |
Compare TRDA, CELU, ALMS, CUE side by side · Screen every company in Pharmaceutical Preparations ↗